Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 21751409)

1.

Improved signal processing and normalization for biomarker protein detection in broad-mass-range TOF mass spectra from clinical samples.

Tracy MB, Cooke WE, Gatlin CL, Cazares LH, Weaver DM, Semmes OJ, Tracy ER, Manos DM, Malyarenko DI.

Proteomics Clin Appl. 2011 Aug;5(7-8):440-7. doi: 10.1002/prca.201000095. Epub 2011 Jul 13.

PMID:
21751409
2.

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF 3rd.

J Urol. 2004 Oct;172(4 Pt 1):1302-5.

PMID:
15371828
3.

A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.

Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL Jr, Qu Y, Potter JD, Winget M, Thornquist M, Feng Z.

Biostatistics. 2003 Jul;4(3):449-63.

4.

Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia.

Forshed J, Pernemalm M, Tan CS, Lindberg M, Kanter L, Pawitan Y, Lewensohn R, Stenke L, Lehtiö J.

J Proteome Res. 2008 Jun;7(6):2332-41. doi: 10.1021/pr070482e. Epub 2008 May 2.

PMID:
18452325
5.
6.

Prostate cancer biomarker discovery using high performance mass spectral serum profiling.

Oh JH, Lotan Y, Gurnani P, Rosenblatt KP, Gao J.

Comput Methods Programs Biomed. 2009 Oct;96(1):33-41. doi: 10.1016/j.cmpb.2009.04.003. Epub 2009 May 6.

PMID:
19423179
7.

Diagnostic potential of serum proteomic patterns in prostate cancer.

Bañez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, McLeod DG, Moul JW, Srivastava S.

J Urol. 2003 Aug;170(2 Pt 1):442-6.

PMID:
12853795
8.
9.

Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.

Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr.

Cancer Res. 2002 Jul 1;62(13):3609-14.

10.

SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.

Skytt A, Thysell E, Stattin P, Stenman UH, Antti H, Wikström P.

Int J Cancer. 2007 Aug 1;121(3):615-20.

PMID:
17410539
11.

A computational platform for MALDI-TOF mass spectrometry data: application to serum and plasma samples.

Mantini D, Petrucci F, Pieragostino D, Del Boccio P, Sacchetta P, Candiano G, Ghiggeri GM, Lugaresi A, Federici G, Di Ilio C, Urbani A.

J Proteomics. 2010 Jan 3;73(3):562-70. doi: 10.1016/j.jprot.2009.11.004. Epub 2009 Nov 13.

PMID:
19914411
12.
13.

Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.

Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, Diaz JI, Semmes OJ.

Clin Cancer Res. 2005 Feb 1;11(3):1073-85.

14.
15.

Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer.

Lu HB, Zhou JH, Ma YY, Lu HL, Tang YL, Zhang QY, Zhao CH.

Jpn J Clin Oncol. 2010 Apr;40(4):336-42. doi: 10.1093/jjco/hyp175. Epub 2010 Jan 20.

16.

Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer.

Hlavaty JJ, Partin AW, Shue MJ, Mangold LA, Derby J, Javier T, Kelley S, Stieg A, Briggman JV, Hass GM, Wu YJ.

Urology. 2003 Jun;61(6):1261-5.

PMID:
12809926
17.

Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.

Cheng HL, Huang HJ, Ou BY, Chow NH, Chen YW, Tzai TS, Wu CJ, Chen SH.

Proteomics Clin Appl. 2011 Apr;5(3-4):121-32. doi: 10.1002/prca.201000011. Epub 2011 Feb 15.

PMID:
21322116
18.

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.

Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L.

Clin Chem. 2005 Jan;51(1):102-12.

19.

Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.

Wang JX, Zhang B, Yu JK, Liu J, Yang MQ, Zheng S.

Chin Med J (Engl). 2005 Aug 5;118(15):1278-84.

PMID:
16117882
20.

Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ.

Am J Clin Oncol. 2008 Apr;31(2):133-9. doi: 10.1097/COC.0b013e318145b98b.

PMID:
18391596
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk